Teva to Present New Data on Multiple Sclerosis and Parkinson’s Disease at the 62nd American Academy of Neurology Annual Meeting

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company’s innovative central nervous system (CNS) portfolio will be presented at the 62^nd American Academy of Neurology Annual Meeting in Toronto, April 10-17,2010.

Featured presentations highlight:

• Pre-clinical data surrounding the unique mechanism of action (MOA) of Copaxone^® (glatiramer acetate injection), further demonstrating how the product works with the immune system. Additional data underscoring the benefit-risk profile of Copaxone^®, the global market-leading relapsing-remitting multiple sclerosis(RRMS) treatment, in both treatment-naive and pre-treated patients.
• An analysis of placebo patients from the ADAGIO study of Azilect^® (rasagiline tablets) inParkinson’s disease (PD), providing information on the natural progression of clinical symptoms of the disease in its early stages. The subgroup analyses provide further insight into the larger effect size seen for rasagiline in ADAGIO patients with greater severity of disease at baseline.
• Pre-clinical and early animal model data demonstrating the immunomodulatory and potential neuroprotective properties of Teva’s investigational, once-daily, oral laquinimod. These data provide further insight into the novel MOA of laquinimod, which is currently being investigated for the treatment of RRMS in two global Phase III clinical trials.
• The innovative study design of the OCTAGON (Optical Coherence Tomography Assessment of Glatiramer acetate On retinal Nerve fiber layer) trial exploring the use of glatiramer acetate in the early treatment of Acute Optic Neuritis
• Results demonstrating the potential role and impact of Neutralizing Antibody (NAb) Testing on multiple sclerosis (MS) treatment decisions